472 related articles for article (PubMed ID: 16556712)
1. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
2. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
4. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
5. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
[No Abstract] [Full Text] [Related]
6. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
[TBL] [Abstract][Full Text] [Related]
7. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
8. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
9. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
[TBL] [Abstract][Full Text] [Related]
10. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
11. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
12. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
13. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
[TBL] [Abstract][Full Text] [Related]
14. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
15. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy].
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H
Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632
[TBL] [Abstract][Full Text] [Related]
16. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
[TBL] [Abstract][Full Text] [Related]
17. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
18. [New immunomodulators in treatment of Graves'ophtalmopathy].
Josseaume C; Lorcy Y
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
[TBL] [Abstract][Full Text] [Related]
19. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
20. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
